PRLog - Feb. 9, 2012 - LINZ, Austria -- Companionship in clinical studies: patient stratification by cost-effective compact sequencing is a first step.
Christoph Reschreiter, Anagnostics(imprint free)
Affinity and Immunogenicity:
Viennese Vela Laboratories are among the leading companies offering efficacy and release testing for biopharmaceuticals under GMP conditions (Good Manufacturing Practice). Vela Laboratories and Anagnostics have agreed upon a strategic partnership in the fields of analytical services and marketing and sales in the area of services for drug discovery units.
‘The fast growing demand in the field of Biosimilars - Comparability Testing results in a need for creative business models. Vela obtained international reputation within the market for complete characterisation of Biopharmaceuticals, Biologics and Biosimilars and is among the top tier suppliers of ICH Q6B conform protein analytics. Anagnostics hybcell technology offers totally new analytical solutions, which we want to offer our customers. Together we can serve our customers more efficiently and comprehensively’
‘Synergies stemming from Anagnostics’
Patient stratification / Affinity Measurement
In a first step Anagnostics’
In a second step Anagnostics’
Leading services for efficacy and release testing of biopharmaceuticals
Vela Laboratories is an internationally active GMP certified contract research/analytics laboratory. Vela offers a broad portfolio of analytical methods, especially for characterisation of proteins. Vela Laboratories offer customer specific analytical services. The highly motivated team of experts focuses on assay development and quality control to serve customers in pre-clinical and clinical developments (market approvals).
Multiplex diagnostics focusing on routine test in drug discovery and clinical diagnostics.
Austrian Anagnostics Bioanalysis focuses on development and production of systems and tests for analytics in drug development (affinity, immunogenicity…)
Since 2005 a young team around molecular geneticist and biochemist Dr. Bernhard Ronacher develops multiplexed analytical systems (hyborg) and tests (hybcells). The patented hybcell is the world’s first cylindrical microarray and core of Anagnostics’
Anagnostics Bioanalysis GmbH | Mag. Christoph Reschreiter
A-4300 St. Valentin | Westbahnstraß